Avalo Therapeutics, Inc. (AVTX): M&A transaction — Avalo Therapeutics sells AVTX-501 milestones and AVTX-007 royalties to ES Therapeutics for $5M

Avalo Therapeutics, Inc.

Closed sale to ES Therapeutics (Armistice affiliate) of rights to milestones from Janssen (AVTX-501) and royalty payments from Apollo (AVTX-007).
Waived all rights under AVTX-611 license agreement with ES and Armistice.
Received $5.0M cash payment upon closing on November 10, 2022.
Board approved under related party policy; Armistice is a significant stockholder.

item 2.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Avalo Therapeutics, Inc. completed a disposition involving ES Therapeutics, LLC for $5.0 million (closed 2022-11-10).

Action: disposition
Counterparty: ES Therapeutics, LLC
Consideration: $5.0 million
Closing: 2022-11-10

Exact text from the filing

The transaction closed on November 10, 2022 and the Company has received the $5.0 million payment from ES.

View on SEC.gov

68 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-029606

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.